BioNTech SE (BNTX) Actualités

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate...

BioNTech to Host Innovation Series R&D Day on November 14, 2024

MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”...

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities